manilatimes3d
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 ...
Buy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward Scenario
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig ...
devdiscourse4d
Novo Nordisk's Obesity Drug Quest: High Stakes and New Challenges
Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...
Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...
thecardiologyadvisor.com4d
Promising Obesity Pharmacotherapies on the Horizon
Monlunabant was evaluated in a phase 2a trial (ClinicalTrials.gov Identifier: NCT05891834) in patients with obesity and metabolic syndrome (N=243). Results showed patients treated with monlunabant ...
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to ...